Abstract
The use of anticoagulation in cardioembolic ischemic stroke is ongoing controversy regarding the effectiveness and safety of the treatment, and factors such as the start time, efficiency in a avoid a new stroke recurrence, the incidence of bleeding complications and time for the start of the oral anticoagulation are a matter of ongoing debate. This review places emphasis on the analysis of the clinical evidence for the efficacy and safety of anticoagulant therapy with emphasis on cardioembolic Stroke, based on an appraisal critical tool of the available clinical trials. From the meta analyses and recommendations from the consensus experts, the use of anticoagulation in the acute phase of the cardioembolic Stroke is not recommended, based on a high risk of hemorrhagic transformation and low efficiency in the control of a new brain embolism; the use of Acetyl Salicilic Acid is considered the most appropriate treatment in the acute phase of the cardioembolic stroke and is required to continue with the design of clinical trials to elucidate the true effectiveness of the heparin within 3 hours of symptoms.
References
Go A, Hylek E, Chang Y. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685-92.
Hallevi H, Albright K. Anticoagulation after Cardio embolic Stroke? To Bridge or not to Bridge Arch Neurol. 2008;65:1169-1173.
Sandercock Peter AG, Gibson Lorna M, Liu Ming. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 3, Art. No. CD000248.
Páramo JA, Panizo E, Pegenaute C, Lecumberri R. Coagulación 2009: una visión moderna de la hemo- stasia. Rev Med Univ Navarra 2009; 53: 19-23.
García J, Carrillo R, Majluf A Fisiología del sistema de coagulación. Gac Méd Méx 2007; 143: 7 – 9.
Pérez F, Bover R. La nueva cascada de la coagu- lación y su posible influencia en el difícil equilibrio entre trombosis y hemorragia. Rev Esp Cardiol 2007;60:1217-9.
Ordobas JP, Climent E, Farmacocinetica y Farmacodinamia de los nuevos anticoagulantes orales. Farm Hosp 2009;33:125-33.
Soria JM. El componente genético de las alteracio- nes de la coagulación y la trombosis. Rev Esp Cardiol 2009;9 (Sup):58B-65B.
Vignoli A, Marcheti M. Differential effect of the low molecular weight heparin, dalteparin, and unfrac- tioned heparin on microvascular cell hemostatic properties. Haematológica 2006; 91: 207 – 214.
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or nei- ther among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
Paciaroni M, Agnelli G. Efficacy and safety of anti- coagulant treatment in acute cardio embolic stroke. A Meta analysis of randomized controlled trials. Stroke 2007; 38: 423 – 430.
Camerlingo M, Salvi P. IV heparin stated within the first 3 hours after onset of symptoms as a treat- ment for acute non lacunar hemispheric cerebral infarction. Stroke 2005; 36: 2415 -2420.
Cervera A, Justicia C. Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in rat. J Neurosci Res 2004;15:565–572.
Michelli S, Agnelli G. Clinical benefit of early anti- coagulation in Cardioembolic stroke. Cerebrovascular Disease 2008; 25: 289 -296.
Adams H, Del Zoppo G. Guidelines for the early management of adults with ischemic stroke. A guide- line for the American Heart/American Stroke Asso- ciation. Stroke 2007; 38: 1655 – 1711.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.